Serum Procalcitonin Levels Distinguish Gram-negative Bacterial Sepsis from Gram-positive Bacterial and Fungal Sepsis
Overview
Affiliations
Background: Serum procalcitonin (PCT) levels differ in patients with bacterial or fungal infections and are significantly elevated in patients with Gram-negative bacteremia. We evaluated the diagnostic accuracy of different inflammatory markers to discriminate sepsis caused by different pathogens.
Materials And Methods: We included 328 episodes of bacteremia from 292 patients with sepsis and 31 patients with suspected sepsis in this study. Medical records of patients who had bacteremia caused by Gram-negative bacteria (Gram-negative), Gram-positive bacteria (Gram-positive) or fungi were reviewed, and information about PCT and other inflammatory markers was recorded. The diagnostic performance of inflammatory markers was calculated via receiver operating characteristic (ROC) curves.
Results: Serum PCT levels in Gram-negative, Gram-positive, and fungal sepsis were 7.47 (interquartile range [IQR]: 1.09-41.26) ng/mL, 0.48 (IQR: 0.15-2.16) ng/mL, and 0.60 (IQR: 0.14-2.06) ng/mL, respectively ( < 0.001). ROC analysis revealed an optimal cut-off value of 2.44 ng/mL for PCT in discriminating Gram-negative sepsis from Gram-positive sepsis, which yielded a sensitivity of 68.4% and a specificity of 77.1%. An optimal cut-off value of 3.11 ng/mL for PCT in discriminating Gram-negative sepsis from fungal sepsis, led to a sensitivity of 63.9% and specificity of 93.3%. Neither PCT nor other inflammatory markers could be used to distinguish between Gram-positive and fungal sepsis.
Conclusion: Serum PCT levels were significantly higher in patients with Gram-negative sepsis than in those with Gram-positive or fungal sepsis. PCT is a potential sensitive biomarker for distinguishing Gram-negative sepsis from Gram-positive and fungal sepsis.
Usefulness of Serum Biomarkers in Predicting Anastomotic Leakage After Gastrectomy.
Ramos D, Gallego-Colon E, Minguez J, Bodega I, Priego P, Garcia-Moreno F Cancers (Basel). 2025; 17(1.
PMID: 39796753 PMC: 11720279. DOI: 10.3390/cancers17010125.
Nisa Z, Ambreen A, Mustafa T Sci Rep. 2024; 14(1):22590.
PMID: 39343776 PMC: 11439925. DOI: 10.1038/s41598-024-71627-5.
Sepsis Biomarkers: Advancements and Clinical Applications-A Narrative Review.
He R, Yue G, Dong M, Wang J, Cheng C Int J Mol Sci. 2024; 25(16).
PMID: 39201697 PMC: 11354379. DOI: 10.3390/ijms25169010.
Patel K, Aden J, Sobieszczyk M, Marcus J Ther Adv Infect Dis. 2024; 11:20499361241255873.
PMID: 38883923 PMC: 11177733. DOI: 10.1177/20499361241255873.
Jing G, Zuo J, Liu Z, Liu H, Cheng M, Yuan M Sci Rep. 2024; 14(1):11551.
PMID: 38773119 PMC: 11109149. DOI: 10.1038/s41598-024-58160-1.